Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation.

AML allogeneic stem cell transplantation clonal landscape extramedullary

Journal

Therapeutic advances in hematology
ISSN: 2040-6207
Titre abrégé: Ther Adv Hematol
Pays: England
ID NLM: 101549589

Informations de publication

Date de publication:
2022
Historique:
received: 15 03 2022
accepted: 05 07 2022
entrez: 2 9 2022
pubmed: 3 9 2022
medline: 3 9 2022
Statut: epublish

Résumé

Although extramedullary manifestations (EMs) are frequent in patients with acute myeloid leukemia (AML), they are often not detected during clinical workup and neither imaging- nor molecularly based diagnostic strategies are established to reveal their existence. Still, the detection of EM is essential for therapeutic decision-making, as EM present with aggressive and resistant disease and since mutational profiling might render patients within a different risk category, requiring personalized therapeutic strategies. Here, we report the case of an AML patient presenting with AML bone marrow (BM) infiltration and molecularly distinct EM at time of diagnosis followed by multiple EM relapses while undergoing several intensive chemotherapies including allogeneic hematopoietic cell transplantations (alloHCTs).

Identifiants

pubmed: 36050938
doi: 10.1177/20406207221115005
pii: 10.1177_20406207221115005
pmc: PMC9425876
doi:

Types de publication

Case Reports

Langues

eng

Pagination

20406207221115005

Informations de copyright

© The Author(s), 2022.

Déclaration de conflit d'intérêts

Competing interests: The authors declare that there is no conflict of interest. C.T. is the CEO and co-owner of AgenDix GmbH.

Références

Haematologica. 2019 Apr;104(4):e147-e150
pubmed: 30467203
Blood. 2011 Oct 6;118(14):3785-93
pubmed: 21795742
Haematologica. 2020 Jun;105(6):1552-1558
pubmed: 31467130
Blood. 2019 Jul 4;134(1):59-73
pubmed: 31023702
Leuk Res. 2004 Oct;28(10):1007-11
pubmed: 15289011
Biomark Res. 2020 Jun 12;8:20
pubmed: 32537166
Haematologica. 2022 Jan 01;107(1):3
pubmed: 34985228
N Engl J Med. 2016 Jul 14;375(2):143-53
pubmed: 27410923
Haematologica. 2010 Jun;95(6):860-3
pubmed: 20513805
Leuk Lymphoma. 2018 Feb;59(2):501-504
pubmed: 28633614
Nat Rev Clin Oncol. 2012 Oct;9(10):579-90
pubmed: 22949046
J Med Case Rep. 2013 Sep 10;7:223
pubmed: 24228906
Biol Blood Marrow Transplant. 2017 Jul;23(7):1087-1094
pubmed: 28396161
Leukemia. 2015 Oct;29(10):2113-6
pubmed: 25787914
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Transplantation. 2012 Apr 15;93(7):744-9
pubmed: 22314337
Biomol Detect Quantif. 2018 Jan 09;15:6-12
pubmed: 29349042

Auteurs

Desiree Kunadt (D)

Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden University of Technology (TU Dresden), Fetscherstrasse 74, 01307 Dresden, Germany.

Sylvia Herold (S)

Institute for Pathology, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.

David Poitz (D)

Institute for Clinical Chemistry, University Hospital Dresden, Dresden, Germany.

Lisa Wagenführ (L)

Department for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.

Theresa Kretschmann (T)

Department for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.

Katja Sockel (K)

Department for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.

Leo Ruhnke (L)

Department for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.

Stefan Brückner (S)

Department for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.

Ulrich Sommer (U)

Institute for Pathology, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.

Frieder Meier (F)

Institute for Pathology, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.

Christoph Röllig (C)

Department for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.

Malte von Bonin (M)

Department for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.

Christian Thiede (C)

Department for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.

Johannes Schetelig (J)

Department for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
DKMS Clinical Trials Unit, Dresden, Germany.

Martin Bornhäuser (M)

Department for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
National Center for Tumor Diseases (NCT) Dresden, Dresden, Germany.
German Cancer Consortium (DKTK) Partner Site Dresden, Dresden, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Friedrich Stölzel (F)

Department for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
German Cancer Consortium (DKTK) Partner Site Dresden, Dresden, Germany.

Classifications MeSH